50+ highly human-simulated NHP autoimmune disease models covering skin, joint, digestive, respiratory and other systems. Deliver preclinical data closest to human physiology, significantly improving drug translation efficiency.

500+ models covering 50+ disease subtypes such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis, catering to target validation, efficacy screening and mechanism research needs in different stages of new drug R&D.

We provide comprehensive target validation and efficacy services utilizing human tissue culture, ex vivo modeling, and organ-on-a-chip platforms. These services elucidate the mechanism of action (MOA) and pharmacological effects of drugs, delivering critical evidence for new drug initiation and clinical translation.

By integrating a multidimensional data matrix from rodent, NHP, and human ex vivo models, and leveraging multi-platform technologies including flow cytometry, pathological analysis, and cellular functional assays, we offer an end-to-end workflow from in vivo efficacy testing to biomarker detection. This ensures comprehensive, precise, and fully traceable data.

Leverage cutting-edge technologies such as proteomics, metabolomics and single-cell sequencing to bridge preclinical and clinical research. Discover and validate disease-related biomarkers, providing data support for clinical protocol design.

Based on 500+ autoimmune disease IND filing experiences, provide end-to-end services including study protocol design, experimental data collation, IND package compilation and problem-solving, ensuring compliant and efficient filing processes.